IN8bio (INAB) Stock Forecast, Price Target & Predictions
INAB Stock Forecast
IN8bio stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
INAB Analyst Ratings
According to 2 Wall Street analysts, IN8bio's rating consensus is 'Buy'. The analyst rating breakdown for INAB stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 03, 2024 | Laidlaw | Buy | Buy | Hold |
| Aug 30, 2022 | H.C. Wainwright | Buy | Initialise |
IN8bio's last stock rating was published by Laidlaw on Jun 03, 2024. The company gave INAB a "Buy" rating, the same as its previous rate.
IN8bio Financial Forecast
IN8bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $16.00M | $5.80M | - | - | - | - | - |
| High Forecast | $16.00M | $5.80M | - | - | - | - | - |
| Low Forecast | $16.00M | $5.80M | - | - | - | - | - |
| # Analysts | 1 | 1 | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
IN8bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. INAB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
IN8bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict INAB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than IN8bio's previous annual EBITDA (undefined) of $NaN.
IN8bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-2.13M | $-2.37M | $-2.60M | $-3.55M | $-3.41M | $-8.04M | $-7.82M |
| High Forecast | $-2.13M | $-2.37M | $-2.60M | $-3.55M | $-2.43M | $-8.04M | $-7.82M |
| Low Forecast | $-2.13M | $-2.37M | $-2.60M | $-3.55M | $-3.89M | $-8.04M | $-7.82M |
| Surprise % | - | - | - | - | - | - | - |
IN8bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. INAB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
IN8bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
IN8bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to INAB last annual SG&A of $NaN (undefined).
IN8bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.04 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.17 | $-0.17 |
| High Forecast | $-0.04 | $-0.05 | $-0.06 | $-0.07 | $-0.05 | $-0.17 | $-0.17 |
| Low Forecast | $-0.04 | $-0.05 | $-0.06 | $-0.07 | $-0.08 | $-0.17 | $-0.17 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, IN8bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to INAB previous annual EPS of $NaN (undefined).
IN8bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | - | - | 4275.00% | Buy |
| RVPH | Reviva Pharmaceuticals | - | - | 706.45% | Buy |
| LIFE | aTyr Pharma | - | - | 478.95% | Buy |
| INMB | INmune Bio | - | - | 362.18% | Buy |
| GANX | Gain Therapeutics | - | - | 332.10% | Buy |
| CUE | Cue Biopharma | - | - | 320.39% | Buy |
| CNSP | CNS Pharmaceuticals | - | - | 284.62% | |
| ZURA | Zura Bio | - | - | 241.30% | Buy |
| PYPD | PolyPid | - | - | 191.55% | Buy |
| ANNX | Annexon | - | - | 170.79% | Buy |
| ANIX | Anixa Biosciences | - | - | 145.10% | Buy |
| WVE | Wave Life Sciences | - | - | 54.29% | Buy |
| PALI | Palisade Bio | - | - | -38.52% | Buy |
| GRCL | Gracell Bio | - | - | -41.46% | Buy |